StockNews.AI
IART
StockNews.AI
150 days

Notice to Long-Term Integra Lifesciences Holdings Corporation (NASDAQ: IART) Shareholders: Grabar Law Investigates Claims on Your Behalf

1. Integra LifeSciences' Board is under investigation for alleged fiduciary breaches. 2. Classes of shareholders can seek returns on litigation expenses incurred. 3. Company recalls products due to unsafe endotoxin levels, harming its reputation. 4. Integra revised guidance for Q2 2023, anticipating a $22 million impairment. 5. FDA regulatory issues may impact future growth and investor confidence.

4m saved
Insight
Article

FAQ

Why Bearish?

Recent product recalls and revenue adjustments negatively impact investor sentiment and stock price, similar to other companies facing regulatory scrutiny.

How important is it?

The investigation could significantly alter investor confidence, impacting stock performance directly.

Why Short Term?

Immediate market reactions to recalls and investigations can lead to quick price fluctuations, but stabilization may occur with proper management and communications.

Related Companies

MDTSYKZBH
PHILADELPHIA, March 22, 2025 (GLOBE NEWSWIRE) -- Grabar Law Office is investigating whether the Board of Directors of Integra LifeSciences Holdings Corp. (NASDAQ: IART) breached their fiduciary duties owed to the Company. Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them.   Learn more or join at: https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/. Contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend’s market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a “recall” of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off. WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/intrga-lifesciences-shareholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085. $IART #IntegraLifeSciences Attorney Advertising Disclaimer Contact:Joshua H. Grabar, Esq.Grabar Law OfficeOne Liberty Place1650 Market Street, Suite 3600Philadelphia, PA 19103Tel:  267-507-6085Email: jgrabar@grabarlaw.com

Related News